BVSN 7.39 Broadvision $BVSN Hit a 52 week low of 7.36

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
BVSN 7.39 Broadvision $BVSN Hit a 52 week low of 7.36 Currently at 7.39 -0.12 -1.60% With a day low of 7.36 and a total volume of 19,400.

BVSN Broadvision Recent Headline News

BroadVision Down 32.7% Since SmarTrend Downtrend Call (BVSN)
Comtex SmarTrend(R) - Tue Nov 04, 9:13AM CST
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 7 months, BroadVision has returned 32.72% as of today's recent price of $7.70.
BVSN: 7.39 (-0.12)

BroadVision Shares Down 31.5% Since SmarTrend's Sell Call (BVSN)
Comtex SmarTrend(R) - Mon Oct 27, 4:51PM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 7 months, BroadVision has returned 31.50% as of today's recent price of $7.84.
BVSN: 7.39 (-0.12)

BroadVision Announces Third Quarter 2014 Results
GlobeNewswire - Wed Oct 22, 4:12PM CDT
BroadVision, Inc. (Nasdaq:BVSN), a leading provider of e-business and engagement management solutions, today reported financial results for its third quarter ended September 30, 2014. Revenues for the third quarter were $3.1 million, compared with revenues of $3.2 million for the second quarter ended June 30, 2014 and $4.0 million for the comparable quarter of 2013.
BVSN: 7.39 (-0.12)

BroadVision Down 28.3% Since SmarTrend Downtrend Call (BVSN)
Comtex SmarTrend(R) - Mon Oct 20, 11:02AM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 7 months, BroadVision has returned 28.26% as of today's recent price of $8.21.
BVSN: 7.39 (-0.12)

27.4% Return Seen to Date on SmarTrend BroadVision Call (BVSN)
Comtex SmarTrend(R) - Mon Oct 13, 9:43AM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 7 months, BroadVision has returned 27.39% as of today's recent price of $8.31.
BVSN: 7.39 (-0.12)

BroadVision Sets Date to Announce Third Quarter Results
GlobeNewswire - Wed Oct 08, 3:10PM CDT
BroadVision, Inc. (Nasdaq:BVSN), a leading provider of e-business and engagement management solutions, today announced that it will release its third quarter 2014 financial results on Wednesday, October 22, at approximately 1:30PM Pacific Daylight Time (PDT).
BVSN: 7.39 (-0.12)

BroadVision Has Returned 22.1% Since SmarTrend Recommendation (BVSN)
Comtex SmarTrend(R) - Mon Oct 06, 9:20AM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 6 months, BroadVision has returned 22.15% as of today's recent price of $8.91.
BVSN: 7.39 (-0.12)

BroadVision Shares Down 23.3% Since SmarTrend's Sell Call (BVSN)
Comtex SmarTrend(R) - Fri Sep 26, 4:54PM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 6 months, BroadVision has returned 23.29% as of today's recent price of $8.78.
BVSN: 7.39 (-0.12)

Shares of BVSN Down 20.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 19, 11:06AM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 6 months, BroadVision has returned 20.31% as of today's recent price of $9.12.
BVSN: 7.39 (-0.12)

Shares of BVSN Down 18.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Sep 12, 9:51AM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 6 months, BroadVision has returned 18.74% as of today's recent price of $9.30.
BVSN: 7.39 (-0.12)

BroadVision Has Returned 17.2% Since SmarTrend Recommendation (BVSN)
Comtex SmarTrend(R) - Fri Sep 05, 9:18AM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 5 months, BroadVision has returned 17.17% as of today's recent price of $9.48.
BVSN: 7.39 (-0.12)

18.6% Return Seen to Date on SmarTrend BroadVision Call (BVSN)
Comtex SmarTrend(R) - Thu Aug 14, 9:45AM CDT
SmarTrend identified a Downtrend for BroadVision (NASDAQ:BVSN) on March 26th, 2014 at $11.45. In approximately 5 months, BroadVision has returned 18.62% as of today's recent price of $9.31.
BVSN: 7.39 (-0.12)

BroadVision Announces Second Quarter 2014 Results
GlobeNewswire - Wed Jul 30, 3:30PM CDT
BroadVision, Inc. (Nasdaq:BVSN), a leading provider of e-business and engagement management solutions, today reported financial results for its second quarter ended June 30, 2014. Revenues for the second quarter were $3.2 million, compared with revenues of $3.0 million for the first quarter ended March 31, 2014 and $4.1 million for the comparable quarter of 2013.
BVSN: 7.39 (-0.12)

BroadVision Releases Vmoso
GlobeNewswire - Tue Jul 29, 3:12PM CDT
BroadVision, Inc. (Nasdaq:BVSN), a global pioneer of e-business solutions, today announced the release of Vmoso, a new platform of engagement unifying virtual, mobile and social communication and collaboration for the enterprise, and myVmoso, its companion "freemium" offering for individual and small office/home office (SOHO) users. Both services are now available in the cloud and accessible online via the Web or mobile apps.
BVSN: 7.39 (-0.12)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 269

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
China's 15th Plan: Key Moves in the Capital Markets

Updated Category News Views 127

Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...

Continue Reading
CStone's CS2009: A Leap in Cancer Treatment Validated

Updated Category News Views 59

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

Continue Reading
NOTHING NINE's Global Ambitions: Paris Show's Impact

Updated Category News Views 83

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Continue Reading
Ambient AI Shows Promise for Boosting Cancer Care Efficiency

Updated Category News Views 13

Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...

Continue Reading
Superteam Wheels Rides Into Spain with RACEIT Deal

Updated Category News Views 63

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Continue Reading
Zinzino Eyes European Market With New Botanical Line

Updated Category News Views 98

Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...

Continue Reading
HCLTech Partners with Rapidus on Semiconductor Future

Updated Category News Views 81

Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...

Continue Reading
ASICS and University of Michigan Launch Innovation Lab

Updated Category News Views 88

Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 412

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

DXC Technology to Announce Q3 Fiscal 2026 Earnings Soon

Updated Category News Views 159

DXC Technology Announces Upcoming Q3 Fiscal 2026 Earnings DXC Technology (NYSE: DXC), a prominent leader in enterprise technology and innovation, has set a date for the release of its financial results for the third quarter of fiscal 2026. The earnings report will be published on a Thursday, after the market closes, providing stakeholders with insights into the company's...

Continue Reading
Jim Cramer Highlights Mettler-Toledo as a Buy Amid Market Woes

Updated Category News Views 188

Jim Cramer Recommends Mettler-Toledo International Inc. On a recent episode of CNBC's popular program, Jim Cramer advised investors to consider buying shares of Mettler-Toledo International Inc. (NYSE: MTD). Cramer's endorsement came after the company reported impressive quarterly results, showcasing strong financial health. Strong Earnings Report from Mettler-Toledo...

Continue Reading
Strategic Alliance Between Vireo and Curio Enhances Growth Opportunities

Updated Category News Views 110

Strategic Partnership Announced Leading cannabis companies Vireo Growth Inc. and Curio Wellness have forged a partnership aimed at leveraging shared resources to tap into the burgeoning cannabis market. This collaboration marks an exciting new chapter for both companies as they work to introduce innovative health and wellness products to consumers. Vireo Growth Inc.: A...

Continue Reading
Anoto Group Reports Second Quarter Results 2024

Updated Category News Views 137

Overview of the Interim Report for 2024 The interim report covering January to June 2024 provides important insights into Anoto Group AB's operations and financial health. Anoto Group continues to be a leader in technology, particularly in optical recognition and digital writing. This report emphasizes key financial metrics and the company's strategic initiatives in a...

Continue Reading
AAOS: Orthobiologics' Future Anchored in Solid Science

Updated Category News Views 9

The Challenge of Orthobiologics: Hype vs. Science Amid the buzz around orthobiologics, it's high time folks face reality: enthusiasm doesn't equal evidence. Dr. Jason Dragoo, the symposium co-chair, hit the nail right on the head—the medical community's chief duty is to sift the wheat from the chaff when it comes to flashy new treatments that lack scientific backing....

Continue Reading